A systematic guide for overseas medical consumable distributors on artwork change control, multilingual IFU approvals, and die-line management
Key Takeaways
Artwork errors are among the top causes of regulatory holds, customs clearance failures, and product recalls in OEM/ODM medical device supply chains.
A formal, phased change control process — with a locked RACI matrix and version-controlled master files — can cut artwork cycle time by 30–50% and eliminate the most common re-print triggers.
Multilingual IFU approval is a manufacturer-owned obligation under EU MDR Article 10(11) and FDA 21 CFR Part 801; distributors cannot carry this responsibility without a formal legal arrangement.
Die-lines are controlled engineering documents, not design templates. Any dimensional change must go through the same change control gate as regulatory content.
SLK Medical’s artwork SOP structure — covering change initiation, impact assessment, cross-functional approval, and obsolescence management — offers a practical template that overseas distributors can adapt for their own private-label or OEM programs.
Introduction: Why Artwork Is the Last Thing You Should Leave to Chance
You’ve done the hard work. The product passed ISO 13485 audits. The silicone foam dressings hit every absorption and adhesion spec. The CE MDR technical file is complete. Your distributor in Frankfurt is waiting.
Then the container clears customs — and gets held. The label is in English only. The IFU doesn’t list the EU-authorized representative. The barcode doesn’t scan. The die-line on the retail box has a bleed that shifts the logo into the seal zone.
This scenario plays out across OEM/ODM medical device supply chains more often than anyone publishes. According to practitioners in the field, artwork-related errors — wrong language, misaligned die-lines, incorrect IFU version, unchecked barcodes — account for a disproportionate share of shipment delays, regulatory queries, and full product recalls. The financial exposure ranges from urgent re-print costs to regulatory non-compliance penalties, and the reputational damage with a hospital procurement committee can be worse than both.
This guide walks through a six-step artwork readiness process designed for overseas medical consumable distributors operating in OEM or ODM arrangements. Each step maps to a concrete action, a document you should hold, and a check that prevents the most common failure modes.
Step 1: Build Your RACI Matrix Before Any Artwork Work Begins
Who does what — and who has final sign-off — must be documented before the first design file opens.
The single most common root cause of artwork delays is ambiguity about ownership. The manufacturer assumes the distributor will review local regulatory content. The distributor assumes the manufacturer’s RA team has handled language requirements. No one checks the barcode ownership. By the time someone raises a question, you are three proof rounds into a launch timeline.
A RACI matrix — Responsible, Accountable, Consulted, Informed — for artwork removes this ambiguity permanently.
What your RACI must cover:
Task | Who typically owns it |
|---|---|
Approved source IFU content | Manufacturer (RA/QA) |
Artwork design and layout | Manufacturer’s packaging team or designated studio |
Regulatory text accuracy by market | Manufacturer RA, validated per target country |
Translation and DTP | Specialized medical translator; DTP review by manufacturer |
Local regulatory review (if required) | Distributor or local RA consultant |
Die-line engineering specification | Manufacturer packaging engineering |
Barcode/UDI generation and ownership | Manufacturer (GS1-assigned prefix) |
Cross-functional approval sign-off | QA + RA + Packaging, minimum |
Print-ready proof check | QA with a two-person redline review |
Final release to print | QA Director or designated authority |
Obsolescence of previous version | QA + Warehouse/Supply Chain |
Under EU MDR Article 10(11), the manufacturer is responsible for providing IFU information in the official language of each Member State where the device is made available. That responsibility cannot be transferred to a distributor without a formal own-brand labeling (OBL) or private-label agreement — and even then, the manufacturer retains technical documentation obligations. Know this before you sign an OEM contract.
Action: Agree on the RACI with your manufacturer counterpart and get it into the Quality Agreement or Technical Agreement before the first artwork brief.
Step 2: Lock Your Artwork Brief and Collect All Approved Source Content
Never open a design file without a complete, signed-off artwork brief and locked source documents.
An artwork brief is the single reference document that controls everything a designer is allowed to put into a label, carton, or IFU. If the brief is incomplete, the designer fills in gaps — and those gaps become compliance errors.
Your artwork brief must specify:
Product name, model number, SKU variants, and product configurations covered
Target markets and corresponding language requirements (mapped per country, not per region)
Regulatory classification and applicable standards (e.g., Class IIa CE MDR, ISO 13485, FDA 510(k) exempt)
Required label elements: CE mark, UDI-DI, lot number, expiry date format, manufacturer name and address, EU AR name and address, storage conditions, sterilization symbols (ISO 15223-1 compliant)
Required IFU elements: indications, contraindications, warnings, instructions, expected performance, maintenance, disposal, batch traceability
Approved claims list (cleared by RA — no unapproved clinical language)
Barcode type and data (EAN-13, GS1-128, 2D DataMatrix for UDI — with ownership confirmed)
Color references (Pantone and CMYK; note which colors are regulatory mandatory vs. brand-only)
Approved source content to collect before briefing:
Approved IFU in source language (English or your master language), version-controlled with effective date
Regulatory-approved translations for each target market (if not available, translation must go through the full approval process — see Step 4)
Confirmed die-line (see Step 3)
All logos in approved vector format (AI, EPS, or PDF/X — no screenshots or JPEGs)
Notified Body certificate reference and CE marking authorization
SLK Medical’s artwork SOP structure formally gates Step 2: no design work starts until all source documents are logged into the controlled document management system and cross-referenced in the artwork brief. This prevents the common failure of an artwork being built against a draft IFU that gets revised before print release.
Step 3: Treat Die-Lines as Engineering Documents, Not Design Templates
A die-line error is a production error. It requires the same change control as a regulatory content change.
Die-lines (also called knives, cutting layouts, or structural templates) define every physical dimension of a packaging component: panel sizes, fold scores, tuck flaps, bleed and safe-zone boundaries, barcode placement zones, and machine-specific tolerance constraints. They are not aesthetic choices. They are controlled engineering documents.
The most expensive artwork mistakes in OEM/ODM programs are die-line errors, precisely because they surface late — often only when the first physical production run fails to fold correctly, or the label doesn’t fit the die-cut window, or the barcode sits in the seal zone and won’t scan.
What a controlled die-line document must include:
Panel numbering and labeling (which panel is front, back, inner flap, outer flap)
Exact dimensions in millimeters, with tolerances
Bleed and safe-zone margins (typically 3mm bleed, 5mm safe zone — verify with your print supplier)
Score and perforations clearly differentiated from cut lines
Machine registration marks and calibration references
Barcode placement zone with minimum quiet zone dimensions
Version number, effective date, approver signature, and status (active / superseded)
Die-line change control rule: Any modification to a die-line — even a 1mm adjustment to accommodate a new market’s language expansion — must go through a formal change request. The impact assessment must check whether the change affects: folding machine compatibility, label fit, symbol placement, regulatory content visibility, barcode scan reliability, and existing inventory status.
If you are receiving die-lines from your OEM manufacturer, request them in locked PDF/X or native CAD format with the version number visible in the file name. A die-line sent as a Word document or unlocked PDF is not a controlled engineering document.
Step 4: Run Multilingual IFU Approvals as a Parallel Workstream, Not an Afterthought
Translation and DTP review take longer than anyone expects. Plan for them in parallel with artwork design, not after.
EU MDR requires IFU content in the official language of every Member State where the device is made available — up to 24 languages for EU-wide distribution. The US FDA requires English-language labeling under 21 CFR Part 801, but many US hospital procurement standards and distributor requirements add Spanish. Middle East markets commonly require Arabic alongside English. Latin America adds Portuguese (Brazil) and Spanish (regional variants).
Multilingual IFU management has two failure modes. The first is getting the translation wrong — wrong medical terminology, safety symbols that don’t match ISO 15223-1, or instructions that are technically correct but ambiguous in the target language. The second is getting the layout wrong — text expansion after translation (German and French expand 20–35% compared to English source) that breaks panel layout, pushes text into margins, or reduces font size below the regulatory minimum (typically 0.6mm x-height for labels, 6-point for IFU body text).
A compliant multilingual IFU approval workflow:
Map languages by market first. Confirm which official languages are required per Member State (use the EC’s MDR language requirements table) before assigning translation work. Do not assume “EU” means one language set.
Engage medical-specialist translators. Generic translation tools — including AI translation without medical domain review — are not acceptable for IFU content. Use translators with documented medical device experience, and build a terminology glossary at the project start to ensure consistency across update cycles.
Run DTP (Desktop Publishing) review per language. After translation, a DTP specialist must reflow the text into the approved layout, check that font sizes remain compliant, and verify that all symbols, diagrams, and warnings remain correctly positioned.
Require back-translation or native-speaker proof. For markets where incorrect language poses patient safety risk, back-translation (translating the output back to source and comparing) is standard practice in regulated industries.
Publish each language as a separate approved variant. Do not treat one multilingual file as universally interchangeable. Each language version carries its own version number and approval record.
Confirm eIFU alignment. If packaging carries a QR code pointing to an electronic IFU, verify that the URL resolves to the correct approved language version for each market. Under EU Commission Implementing Regulation (EU) 2021/2226, eIFU eligibility and the packaging QR code are controlled separately from the printed document.
Maintain a cross-language version synchronization log. When the source IFU changes, every translated version must be flagged for update. The log tracks which translations are current and which are pending revision.
SLK Medical’s IFU management process assigns a dedicated RA owner per major market cluster — EU, US, Middle East, Asia-Pacific — to ensure language requirement tracking is active and current, not reactive. This structure is directly replicable for distributors building a private-label program.
Step 5: Run a Structured Cross-Functional Approval Before Any Print Release
No artwork should reach a print supplier without documented approval from QA, RA, and Packaging — minimum.
The approval stage is where most artwork programs break down in practice. Reviews happen informally over email. Comments arrive in three different document versions. The final approver signs off on version 4 of a file while the print supplier has already received version 5. Audit inspectors find no documented evidence of approval for the version actually in production.
A structured approval process has three characteristics: it is documented, it is sequential where required, and it is conclusive.
Minimum approval matrix for medical device artwork:
Function | Review scope | Sign-off required |
|---|---|---|
Regulatory Affairs | Regulatory text accuracy, claims, market-specific requirements, IFU version alignment | Yes |
Quality Assurance | Version control, audit trail completeness, SOP compliance, obsolescence check | Yes (final gate) |
Packaging/Engineering | Die-line accuracy, print spec compliance, barcode placement | Yes |
Medical/Clinical (if claims are involved) | Clinical accuracy of performance claims | Yes (where applicable) |
Local Market / Distributor RA | Local regulatory content, language accuracy sign-off | Yes (per market) |
Pre-print proof verification checklist:
Before releasing any file to a print supplier, complete a two-person redline check against the approved master:
Text match: compare every word, number, and symbol against the approved source document. Do not rely on visual comparison alone.
Barcode verification: scan every barcode and QR code on the proof with a handheld scanner. Check GS1 compliance and minimum quiet zone.
Die-line alignment: verify that artwork content sits within safe zones on every panel.
Color accuracy: check Pantone spot colors and CMYK values against approved color references.
Symbol compliance: verify that all ISO 15223-1 symbols are the current approved versions.
UDI check: confirm UDI-DI format matches the registered device identifier.
Document the results of this check as a controlled record, retained in the device history record.
Step 6: Implement Formal Change Control for Every Artwork Revision
After first approval, every change — however minor — requires a change request, impact assessment, and re-approval.
This step is where distributors most commonly create compliance exposure without realizing it. A label gets updated to add a new EU authorized representative address. Someone sends the updated text to the print supplier by email. The artwork file is modified and printed. No change request is raised. No impact assessment is performed. No QA sign-off is on file.
When an inspector audits the device history record, the label in the field does not match the approved artwork version in the QMS. That is a non-conformance. If it affects patient safety information, it becomes a potential recall trigger.
A six-step artwork change control process:
Initiate. Any person — regulatory, supply chain, marketing, or a distributor — who identifies a required change submits a formal Artwork Change Request (ACR) specifying the change, the reason, and the affected products and markets.
Impact assess. QA and RA jointly assess impact on: regulatory text, GTIN/barcode, existing inventory (quarantine if needed), die-line fit, stability records, translation requirements, and UDI registration.
Review and approve. The cross-functional team reviews the revised artwork against the change scope. No changes outside the approved change scope are permitted on the same revision pass.
Implement. The revised artwork file is created, version-incremented, and submitted for proof verification (as per Step 5). The new version number and effective date are recorded in the artwork register.
Retire obsolete materials. Old artwork files are marked superseded in the DMS. The print supplier is notified to destroy or return obsolete plates and knives. Any remaining inventory of the old version is assessed for market clearance or segregation.
Close and record. The change request is closed with documented evidence of completion: revised artwork approval record, print supplier acknowledgment, inventory disposition record, and updated artwork register entry.
SLK Medical’s artwork SOP formalizes the retirement step explicitly — a common gap in smaller OEM programs where obsolete plates continue circulating in the print supply chain, creating mixed-version risk in production.
Common Failure Modes and How to Prevent Them
Failure mode | Root cause | Prevention |
|---|---|---|
Wrong language on shipped product | Language-market mapping done late or skipped | Complete mapping in artwork brief (Step 2) before any design work |
Die-line error found at production | Die-line not version-controlled; change made without impact assessment | Treat die-lines as engineering documents; gate all changes through Step 6 |
IFU version mismatch between label and DMS | No cross-reference check between packaging and IFU version | Step 5 pre-print checklist includes IFU version alignment check |
Barcode fails scan at customs | Barcode generated without GS1 validation; quiet zone compromised | GS1 compliance verified in Step 5; die-line specifies quiet zone |
Text expansion breaks layout after translation | DTP review not performed per language | Step 4 mandates DTP review for every language variant |
Obsolete artwork printed | Print supplier holds old files; no notification of version change | Step 6 includes formal supplier notification and plate retirement |
No audit trail for approved version | Approvals done by email without document control | Steps 5 and 6 require formal records in QMS; email is not a controlled record |
How SLK Medical Approaches Artwork Readiness
SLK Medical, a specialist manufacturer of advanced wound care dressings including silicone foam, antimicrobial silver (Ag), and super-absorbent variants, operates across EU MDR, FDA, and ISO 13485 frameworks simultaneously. The complexity of managing multiple market registrations, multilingual IFU sets, and OEM/private-label programs for overseas distributors drove the development of a structured artwork SOP that covers each stage described in this guide.
Key structural features of SLK Medical’s approach that overseas distributors can replicate:
Single source of truth for artwork master files: all approved artwork versions are held in a controlled DMS with access rights limited to designated QA and RA roles. Print suppliers receive only print-ready PDFs released through the DMS, not editable source files.
Dedicated RA ownership per market cluster: rather than treating all IFU languages as one workstream, SLK assigns RA owners for each cluster (EU, US, Middle East, APAC) who maintain current awareness of language requirement changes.
Explicit obsolescence tracking: every time a new artwork version is approved, the change control record includes a sign-off confirming that the print supplier has acknowledged the change and has destroyed or returned obsolete plates.
Pre-launch artwork readiness checklist: before any new product ships to a distributor market, the QA team runs a checklist that confirms: correct language version, correct IFU version cross-reference, barcode scan confirmation, die-line sign-off, and EU AR details (for EU markets).
For distributors evaluating a new OEM/ODM manufacturer partner, asking to review the manufacturer’s artwork SOP structure — not just the ISO 13485 certificate — is a practical way to assess operational readiness. A manufacturer without a formal artwork control process transfers that compliance risk downstream to the distributor.
Your Artwork Readiness Checklist
Before committing to a first production run with an OEM/ODM manufacturer, confirm:
Governance
RACI matrix agreed and in the Quality Agreement
Artwork DMS identified; access rights confirmed
Version numbering convention agreed
Source Documents
Approved IFU in source language, version-controlled
Language-market map completed for all target markets
Approved translations confirmed (or translation workflow underway)
Die-line received in controlled format with version number
Design and Layout
Artwork brief signed off before design begins
Approved source content only used in design
DTP review completed per language variant
Approval
Cross-functional approval matrix completed (RA, QA, Packaging minimum)
Two-person redline check completed against master
Barcode and QR codes verified by scan
Die-line alignment confirmed on proof
Change Control
Change control SOP agreed with manufacturer
Supplier notified of current approved version
Obsolete materials retirement process confirmed
Conclusion
Artwork delays and errors are not random events. They follow predictable patterns: missing source documents, informal approval processes, die-lines treated as editable templates, translation managed as an afterthought, and change control that exists on paper but not in practice.
The six steps in this guide — RACI setup, artwork briefing, die-line control, multilingual IFU management, structured approval, and formal change control — address each of these patterns directly. Applied consistently, they reduce re-print cycles, protect regulatory standing, and give distributor teams a defensible audit trail when a regulatory authority or hospital procurement committee asks for documentation.
For overseas medical consumable distributors building or expanding a private-label or OEM program, starting from a manufacturer whose artwork SOP already covers these steps is the fastest path to readiness. Requesting that SOP — and reviewing it critically against the framework in this guide — is a practical due diligence step that pays for itself on the first shipment.
To learn more about SLK Medical’s OEM/ODM capabilities, artwork support process, and the documentation pack available to distributor partners, visit SLK Medical or request a partnership brief directly.
